A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Inhye E. Ahn, Jennifer R. Brown, Josie Montegaard et al.|Blood|2023Cited by 1